丹麦ROSE人群筛查研究中抗骨质疏松药物的使用情况
该研究基于丹麦ROSE随机人群筛查试验,纳入65-81岁女性,比较FRAX联合DXA两步筛查与机会性筛查(常规诊疗)对 Antiosteoporotic 药物处方、依从性和持续性的影响。筛查组启动抗骨质疏松药物治疗的比例显著更高,但两组依从性和持续性无差异;31.7%被建议起始治疗者未遵从建议。
要点
- 筛查组启动抗骨质疏松药物治疗的比例显著高于常规诊疗组。
- 两组在用药依从性和持续性上无显著差异。
- 31.7%被建议起始治疗者未遵从建议,高龄与更高起始治疗可能性相关。
核心结论
- 采用FRAX联合DXA的骨质疏松筛查增加了筛查组抗骨质疏松药物的总体使用,但依从性和持续性无差异。
- 相当大比例被建议起始治疗的参与者未启动治疗。
研究设计与样本
- 丹麦ROSE研究为基于人群的随机对照筛查试验,纳入65-81岁女性随机分入两步筛查组(FRAX后对高危者行DXA)或机会性筛查(常规诊疗)组。
- 本子研究基于意向性治疗人群,利用丹麦登记数据评估抗骨质疏松药物兑换率、依从性和持续性,34,229名女性中30,719名基线未接受治疗。
主要发现
- 筛查组启动抗骨质疏松药物治疗的参与者显著多于常规诊疗组,但两组依从性和持续性无差异。
- 年龄较高与启动药物治疗的可能性较高相关。
- Charlson合并症评分低(=1)与较高的治疗启动相关,但与较低的依从性和持续性相关。
- 被建议起始治疗的参与者中31.7%未遵从建议。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Use of antiosteoporotic medication in the population-based, risk-stratified osteoporosis strategy evaluation (ROSE) screening study, comparing the use of FRAX followed by DXA with usual care, was examined. Screening increased the overall use of medication. Being recommended treatment by the hospital and higher age increased the likelihood of starting medication, but, nevertheless, a large percentage opted not to start treatment. INTRODUCTION: The aim of the study was to examine the impact on medication prescription, adherence, and persistence of osteoporotic medicine in the randomized population-based ROSE screening study for osteoporosis. METHODS: The Danish ROSE study included a population-based random sample of women aged 65-81 years randomized to either a two-step screening program consisting of FRAX followed by DXA for high-risk participants or opportunistic screening for osteoporosis (usual care). This sub-study on the intention-to-treat population examined the impact of the screening program on antiosteoporotic medication redemption rates, adherence, and persistence using Danish registers. RESULTS: A total of 30,719 of 34,229 women were treatment-naïve. Significantly more participants in the screening group started on antiosteoporotic medication, but no differences in adherence and persistence rates were found. Higher age was associated with a higher likelihood of starting medication. A low Charlson comorbidity score (= 1) was associated with higher treatment initiation but lower adherence and persistence of antiosteoporotic treatment. A total of 31.7% of participants advised to initiate treatment did not follow the advice. CONCLUSIONS: Screening for osteoporosis using FRAX followed by DXA increased the overall use of antiosteoporotic medication in the screening group without differences in adherence and persistence rates. A large percentage of participants advised to initiate treatment did nevertheless fail to do so.
引用
- Høiberg MP, Rubin KH, Holmberg T, et al. Use of antiosteoporotic medication in the Danish ROSE population-based screening study. Osteoporos Int. 2019. PMID: 30911782. doi:10.1007/s00198-019-04934-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。